SAN DIEGO, March 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), have until Tuesday, April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMe ...

Core Viewpoint - A lawsuit has been filed against TransMedics Group, Inc. and certain senior executives for potential violations of federal securities laws, alleging misrepresentation and fraudulent practices [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Massachusetts, captioned Jewik v. TransMedics Group, Inc. et al, No. 25-cv-10385 [2]. - Investors have until April 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - TransMedics is a commercial-stage medical technology company known for its "Organ Care System" (OCS), which maintains donor organs' viability before transplant [3]. Group 3: Allegations - The complaint alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics, misrepresented safety practices, and lacked proper safety oversight [4]. - Specific accusations include overcharging for OCS and misappropriating corporate resources, leading to a stock price decline of approximately 4% from $86.99 to $83.14 between February 21 and February 23, 2024 [5]. Group 4: Stock Performance and Impact - Following the resignation of the CFO and a narrowed financial outlook in December 2024, a report by Scorpion Capital in January 2025 claimed that TransMedics' growth was driven by anti-competitive schemes and billing fraud, resulting in a further 5% decline in stock price from $72.55 to $68.81 between January 8 and January 10, 2025 [6].

Core Viewpoint - A class action securities lawsuit has been filed against TransMedics Group, Inc. alleging securities fraud that affected investors between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is alleged that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [2]. - The aforementioned actions subjected TransMedics to increased scrutiny and regulatory risks, leading to materially false and misleading statements about its business and operations [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until April 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/transmed ...

Core Viewpoint - A class action securities lawsuit has been filed against TransMedics Group, Inc. alleging securities fraud that affected investors between February 28, 2023, and January 10, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [2]. - It is alleged that the company engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight [2]. - The aforementioned actions subjected TransMedics to increased scrutiny and regulatory risks, leading to materially false and misleading statements about its business and operations [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until April 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the Class Period from February 28, 2023, to January 10, 2025, with a lead plaintiff deadline set for April 15, 2025 [1]. Allegations Against TransMedics - The complaint alleges that TransMedics engaged in unethical practices, including the use of kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3]. - It is claimed that TransMedics engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight, which increased the company's regulatory risk [3]. Lead Plaintiff Process - Investors in TransMedics can seek to be appointed as a lead plaintiff representative by April 15, 2025, or may choose to remain absent from the class [4]. - The lead plaintiff will represent the interests of all class members and select counsel to direct the litigation [4].

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for allegedly misleading investors regarding business practices and safety issues during the Class Period from February 28, 2023, to January 10, 2025 [1][3]. Company Overview - TransMedics Group, Inc. is a medical technology company based in Andover, Massachusetts, specializing in transplant services, including the Organ Care System (OCS), which is a portable organ preservation system [2]. Allegations - The lawsuit claims that TransMedics engaged in unethical practices, including kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. - It is also alleged that the company concealed safety issues and lacked proper safety oversight [3]. Impact on Stock Price - Following the revelation of these allegations, TransMedics' stock price dropped significantly. On February 22, 2024, the stock fell by $2.18 (2.5%) to close at $84.81 after a letter from U.S. Rep. Paul Gosar accused the company of misappropriating resources [4]. - On January 10, 2025, after a report from Scorpion Capital, the stock fell by $3.74 (5%) to close at $68.81, and further declined by $4.76 (6.9%) to close at $64.05 on January 13, 2025 [5].

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to b ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=134056&from=4CLASS PERIOD: Febru ...

Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and covers purchasers of TransMedics securities from February 28, 2023, to January 10, 2025 [1]. - Investors have until April 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. Group 2: Allegations Against TransMedics - Specific allegations include unsafe practices and a lack of safety oversight, which increased regulatory scrutiny risks [3]. - A letter from U.S. Representative Paul Gosar on February 21, 2024, accused TransMedics of misconduct, leading to a decline in stock price following its public disclosure [4]. - A report from Scorpion Capital on January 10, 2025, further accused TransMedics of overbilling and providing rejected organs to patients, resulting in additional stock price declines [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased TransMedics securities during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in related class action cases [7].